At the time of writing, Coherus Biosciences Inc [CHRS] stock is trading at $2.51, up 3.29%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CHRS shares have gain 4.58% over the last week, with a monthly amount glided 13.57%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 8, April 2024, Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting. In a post published today on Yahoo Finance, – In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion –– Mechanism may enhance antitumor responses with immunotherapy –– First novel immuno-oncology product candidate discovered and developed by Coherus –– The CHS-1000 IND submission is planned for Q2 2024 –.
From an analyst’s perspective:
Coherus Biosciences Inc [NASDAQ: CHRS] stock has seen the most recent analyst activity on November 17, 2023, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $11. Previously, Maxim Group downgraded its rating to Hold on November 08, 2023. On July 24, 2023, Citigroup initiated with a Buy rating and assigned a price target of $12 on the stock. Truist started tracking the stock assigning a Buy rating and suggested a price target of $24 on May 01, 2023. UBS upgraded its rating to a Buy but $11 remained the price target by the analyst firm on March 28, 2023. UBS started tracking with a Neutral rating for this stock on June 14, 2022, and assigned it a price target of $7. In a note dated March 07, 2022, JP Morgan downgraded an Neutral rating on this stock but restated the target price of $15.
For the past year, the stock price of Coherus Biosciences Inc fluctuated between $1.43 and $8.65. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Coherus Biosciences Inc [NASDAQ: CHRS] shares were valued at $2.51 at the most recent close of the market. An investor can expect a potential return of 258.57% based on the average CHRS price forecast.
Analyzing the CHRS fundamentals
According to Coherus Biosciences Inc [NASDAQ:CHRS], the company’s sales were 257.24M for trailing twelve months, which represents an 101.81% jump. Gross Profit Margin for this corporation currently stands at 0.38% with Operating Profit Margin at -0.79%, Pretax Profit Margin comes in at -0.93%, and Net Profit Margin reading is -0.92%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is 1.36 and Total Capital is -0.68. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.46.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.44 points at the first support level, and at 2.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.56, and for the 2nd resistance point, it is at 2.62.
Coherus Biosciences Inc [CHRS] reported earnings per share of -$0.62 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.12/share, meaning a difference of -$0.5 and a surprise factor of -416.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.27 per share as compared to estimates of -$0.27 per share, a difference of $0 representing a surprise of 0.00%.
Ratios To Look Out For
It is important to note that Coherus Biosciences Inc [NASDAQ:CHRS] has a current ratio of 1.43. Also, the Quick Ratio is 1.24, while the Cash Ratio stands at 0.31. Considering the valuation of this stock, the price to sales ratio is 1.09.
Transactions by insiders
Recent insider trading involved Lanfear Dennis M, President & CEO, that happened on Nov 22 ’23 when 0.22 million shares were sold.
